Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial

By sjmartinez • June 4, 2024

Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. J Crohns Colitis. 2024 Jun 3;18(6):885-894. doi: 10.1093/ecco-jcc/jjae007. PMID: 38245818; PMCID: PMC11147797.

Tags: Cedars Sinai DoM, Digestive Diseases, endoscopic improvement–histologic remission, Etrasimod, mucosal healing, Publications, S1P receptor modulator, ulcerative colitis

Comparison, Agreement, and Significance Cutoffs of 18F-Flurpiridaz PET Myocardial Blood Flow Quantitation Methods and Software Packages

Packard RRS, Buckley C, Cooke CD, Moody JB, Renaud JM, Slomka P, Thompson D, Van Kriekinge SD, Van Train KF, Wangerin KA, Maddahi J. Comparison,[...]

The REgistry of Flow and Perfusion Imaging for Artificial INtelligEnce with PET(REFINE PET): Rationale and Design

Ramirez G, Lemley M, Shanbhag A, Kwiecinski J, Miller RJH, Kavanagh PB, Liang JX, Dey D, Slipczuk L, Travin MI, Alexanderson E, Carvajal-Juarez I, Packard[...]

Interaction between haploinsufficiency of PTPN2 and patient microbiome promotes autoimmune arthritis in mice

Sendo S, Vela AJ, Ro M, Thiruppathy D, Wilkinson EL, Zhao Z, Hsieh WC, Yang S, Coras R, Bergot AS, Guma M, Nguyen A, McBride[...]